酒精与心血管代谢危险因素对肝硬化十年风险的影响:丹麦人群队列研究
该研究基于丹麦国家健康调查2010-2017年354,624名无肝硬化参与者,评估酒精摄入与心血管代谢危险因素对肝硬化风险的独立及联合关联。中位随访3.3百万人年期间1211人发生肝硬化,酒精摄入是最主要可改变危险因素,归因分数达59.9%,重度饮酒者中心血管代谢因素影响不显著。
要点
- 每周饮酒>42杯者10年肝硬化绝对风险达4.6%,远高于低饮酒量者。
- 肥胖、糖尿病、高血压和吸烟分别与肝硬化风险升高2-3倍相关。
- 每周饮酒>28杯时,心血管代谢危险因素对肝硬化风险的影响不显著。
核心结论
- 酒精摄入是肝硬化最主要的可改变危险因素,归因分数为59.9%。
- 肥胖、糖尿病、高血压和吸烟增加肝硬化风险,但效应较重度饮酒小。
- 每周饮酒超过28杯时,心血管代谢危险因素的影响不显著。
研究设计与样本
- 基于丹麦国家健康调查2010-2017年的前瞻性人群队列。
- 纳入354,624名无肝硬化诊断的参与者,中位年龄55岁。
主要发现
- 随访3.3百万人年期间,1,211人发生肝硬化。
- 每周饮酒1-7、8-14、15-28、29-42和>42杯者的10年肝硬化绝对风险分别为0.14%、0.29%、0.68%、2.0%和4.6%。
- BMI≥30 kg/m²、糖尿病、高血压和吸烟分别与肝硬化风险升高2至3倍相关。
- 血脂异常总体与肝硬化风险无关,但在每周饮酒8-14杯者中与风险增加相关。
- 肥胖、糖尿病和高血压在每周饮酒1-28杯者中增加风险,但在>28杯者中无显著影响;吸烟在所有饮酒水平均增加风险。
关键数值与推荐
- 归因分数:酒精摄入59.9%,高血压29.3%,吸烟21.2%,BMI≥30 kg/m² 13.8%,糖尿病9.0%,血脂异常无统计学显著归因分数。
临床怎么用
- 应将减少酒精摄入作为肝硬化预防的首要优先措施。
- 对于饮酒人群,戒烟和心血管代谢风险管理应作为补充预防目标。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The combined effects of alcohol consumption and cardiometabolic risk factors on cirrhosis risk are increasingly recognized. We examined the independent and combined associations of alcohol consumption and cardiometabolic risk factors with cirrhosis risk. METHODS: We included 354,624 participants from the Danish National Health Surveys 2010-2017 without a diagnosis of cirrhosis. We estimated 10-year absolute and relative cirrhosis risks, population attributable fractions (PAFs), and supra-additive interactions according to alcohol consumption and cardiometabolic risk factors. RESULTS: Participants had a median age of 55 years; 12% reported ≥15 drinks/week, 17% had a BMI ≥30 kg/m2, 5% had diabetes, 28% had hypertension, 21% smoked, and 18% had dyslipidemia. During 3.3 million person-years of observation, 1,211 developed cirrhosis. Alcohol consumption strongly affected the risk of cirrhosis (10-year absolute risks of 0.14%, 0.29%, 0.68%, 2.0% and 4.6% for 1-7, 8-14, 15-28, 29-42, and >42 drinks per week, respectively). BMI ≥30 kg/m2, diabetes, hypertension, and smoking were each associated with two-to threefold higher risk. Dyslipidemia was not associated with cirrhosis risk overall but was associated with increased risk among participants drinking 8-14 drinks/week. BMI ≥30 kg/m2, diabetes, and hypertension increased risk among consumers of 1-28 drinks per week but not for > 28 drinks/week. Smoking increased risk across all alcohol levels, with indications of supra-additive interaction. PAFs were 59.9% for alcohol consumption, 29.3% for hypertension, 21.2% for smoking, 13.8% for BMI ≥30 kg/m2, and 9.0% for diabetes; dyslipidemia had no statistically significant PAF. CONCLUSIONS: Obesity, diabetes, hypertension, and smoking, but not dyslipidemia, increased cirrhosis risk, with modest effects compared to heavy alcohol use. The impact of cardiometabolic risk factors was non-significant above 28 drinks per week, underscoring alcohol as the principal driver of cirrhosis risk in heavy drinkers. IMPACT AND IMPLICATIONS: The introduction of the MetALD nomenclature has highlighted the need to understand how alcohol consumption and cardiometabolic risk factors jointly contribute to cirrhosis risk, but whether these interactions differ by level of alcohol intake has remained unclear. In this population-based cohort, alcohol consumption was the dominant modifiable risk factor, with approximately 60% of cirrhosis cases attributable to drinking above the minimum-risk reference range, whereas the attributable fractions for individual cardiometabolic and lifestyle risk factors were substantially smaller. Supra-additive associations were observed for obesity, diabetes, and hypertension, mainly at alcohol intakes of up to 28 drinks/week, whereas smoking showed a supra-additive association with alcohol across all consumption levels; dyslipidemia showed no clear contribution. These findings support alcohol reduction as the primary prevention priority, while indicating that smoking cessation and cardiometabolic risk management should be considered complementary prevention targets, particularly among people who drink alcohol.
引用
- Rønn JH, Jepsen P, Mellinger J, et al. Alcohol, cardiometabolic risk factors, and cirrhosis: Ten-year risk estimates from a population-based Danish cohort. J Hepatol. 2026. PMID: 42637052. doi:10.1016/j.jhep.2026.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。